Optimizing hereditary angioedema management through tailored treatment approaches.
Hereditary angioedema (HAE) is a rare but serious and potentially life threatening autosomal dominant condition caused by low or dysfunctional C1 esterase inhibitor (C1-INH) or uncontrolled contact pathway activation. Symptoms are characterized by spontaneous, recurrent attacks of subcutaneous or submucosal swellings typically involving the face, tongue, larynx, extremities, genitalia or bowel. The prevalence of HAE is estimated to be 1:50,000 without known racial differences. It causes psychological stress as well as significant socioeconomic burden. Early treatment and prevention of attacks are associated with better patient outcome and lower socioeconomic burden. New treatments and a better evidence base for management are emerging which, together with a move from hospital-centered to patient-centered care, will enable individualized, tailored treatment approaches.
a Department of Immunology, Barts Health NHS Trust , London , UK.
Iman H
IH
Nasr
a Department of Immunology, Barts Health NHS Trust , London , UK.
Ania L
AL
Manson
a Department of Immunology, Barts Health NHS Trust , London , UK.
Humaid A
HA
Al Wahshi
a Department of Immunology, Barts Health NHS Trust , London , UK.
Hilary J
HJ
Longhurst
D054179:Angioedemas, Hereditary / Q000453:epidemiology / Q000628:therapy*; D050718:Complement C1 Inhibitor Protein / Q000235:genetics; D003710:Demography; D006297:Health Services Accessibility; D006801:Humans; D010346:Patient Care Management; D057285:Precision Medicine; D016896:Treatment Outcome
D050718:Complement C1 Inhibitor Protein
C1-inhibitor; attenuated androgens; bradykinin; ecallantide; factor XIIa; hereditary angioedema; home therapy; icatibant; kallikrein; prekallikrein; quality of life